CD Biosynsis offers comprehensive Insect Cells Genome Editing Services, utilizing advanced CRISPR-based precision tools to modify this versatile host for recombinant protein expression, gene function studies, and vaccine development. Insect cell lines (e.g., Sf9, Hi5, S2) are widely used in the Baculovirus Expression Vector System (BEVS) for producing complex recombinant proteins, particularly those requiring eukaryotic folding, disulfide bond formation, and PTMs (Post-Translational Modifications). Our services provide access to advanced CRISPR technologies, including CRISPR-Cas9 for stable integration and multi-gene editing, Base Editing for single-nucleotide precision, and CRISPRi for tunable gene repression. We specialize in providing highly efficient, stable, and markerless modifications that accelerate the optimization of insect cell lines for enhanced yield, improved folding efficiency, and tailored glycosylation profiles.
Get a QuoteEffective strain engineering in insect cell lines is crucial for optimizing the Baculovirus Expression Vector System (BEVS) . Our platform focuses on maximizing the insect cell host's natural advantages while addressing inherent limitations, such as non-human-compatible glycosylation. We utilize the flexibility of CRISPR-Cas9 to perform both stable genomic knock-ins (e.g., integrating mammalian glycosylation enzymes) and gene knockouts (e.g., eliminating native protease genes or native glycosyltransferases). This capability is vital for managing the complex interplay between baculovirus-driven gene expression and the host's cellular machinery, ensuring high yield and desired product quality.
CRISPR-Cas9 System
Standard editing platform for targeted DNA double-strand breaks (DSBs), optimized for efficient integration (Knock-in) into safe harbor loci and multi-gene deletions (Knockout).
Base Editing (BE)
DSB-free system for highly efficient, clean single-nucleotide conversions (C>T or A>G), ideal for promoter/UTR tuning and optimizing native enzyme activity (e.g., in the folding pathway).
CRISPR Interference (CRISPRi)
Tunable and reversible gene knockdown (repression) for rapidly optimizing the expression balance of host factors or managing metabolic flux without permanent edits.
Gene Knockout (KO)
Permanent deletion or disruption of single or multiple target genes (e.g., proteases, O-linked glycan enzymes) to enhance product stability and quality.
Targeted Gene Knock-in
Accurate integration of expression cassettes or metabolic pathway genes (e.g., human glycosyltransferases) into safe harbor loci for stable, constitutive expression.
Multiplex Editing
Simultaneous targeting of multiple genes using gRNA arrays and marker recycling to accelerate the construction of advanced chassis strains (e.g., complex glycoengineered lines).
Humanized Glycoengineering
Knockout of native $\beta(1,4)$-galactosyltransferase and $\alpha(1,3)$-fucosyltransferase genes and knock-in of mammalian counterparts to produce human-compatible N-glycans.
Enhanced Protein Folding
Editing chaperone and PDI (Protein Disulfide Isomerase) genes to improve the folding capacity of the Endoplasmic Reticulum (ER), maximizing the yield of complex, soluble proteins.
Protease Deficiency
Deletion of host cell protease genes (e.g., cathepsins, metalloproteases) that degrade the secreted recombinant product, ensuring product stability and integrity.
A systematic process for rational design, precise editing, and stable clone isolation.
1. Rational Design & Target Identification
2. Editing Tool Construction & Delivery
3. Clone Isolation & Screening
4. Verification & Stable Cell Line Delivery
Identify target loci (KO or KI) based on yield goals (e.g., protease removal) or quality goals (e.g., glycoenzyme modification).
Design high-specificity gRNAs, repair templates with homology arms, and expression cassettes (e.g., NLS-Cas9/BE).
Determine the optimal editing tool (Cas9, BE, or CRISPRi) and delivery method (plasmid or RNP) for the specific insect cell line (Sf9, Hi5).
Construct the editing tool expression system and necessary DNA parts.
Deliver the editing components into the insect host cells via optimized lipofection or electroporation protocols.
Apply antibiotic selection or FACS sorting to enrich for stable integration clones or successful editing events.
Genotype verification via junction PCR and definitive sequencing of the edited locus to confirm clean edit.
Phenotypic validation of the final clone for stable expression and product functionality over multiple passages.
Delivery of the verified insect cell master cell bank (MCB) and comprehensive documentation.
Targeted Glycoengineering
Expertise in multiplex KO/KI to humanize the insect cell glycosylation pathway, solving a major limitation of the BEVS system for therapeutic protein production.
Stable Genomic Integration
CRISPR-mediated knock-in ensures permanent integration of transgenes into defined host cell genomic loci, eliminating the reliance on unstable viral vectors for constitutive expression.
Enhanced Folding Capacity
Gene editing tools (BE/CRISPRi) are used to tune the expression of native chaperones (e.g., BiP) and folding enzymes, optimizing the ER environment for complex protein production.
Full CRISPR Toolset
Access to Cas9, Base Editing, and CRISPRi ensures the most efficient and precise modification can be chosen for any target: permanent KO, subtle tuning, or reversible repression.
1. Why use insect cells for recombinant protein production?
Insect cells (e.g., Sf9, Hi5) are eukaryotic, providing the machinery for complex folding, PTMs, and high-level, fast expression via the Baculovirus Expression Vector System (BEVS), often yielding highly active protein at scale.
2. What is the main limitation of wild-type insect cell glycosylation?
Wild-type insect cells add non-mammalian, paucimannose or high-mannose N-glycans, which can cause immunogenic issues or alter therapeutic efficacy in humans. Genome editing is used to "humanize" these glycans.
3. Can you perform both Gene Knockout and Gene Knock-in in a single project?
Yes. A common strategy involves multiplex knockout of native glycosylation genes (e.g., FUT/GNT) and subsequent stable knock-in of mammalian glycosyltransferases to create a fully humanized insect cell chassis.
4. How is the editing system delivered into insect cells like Sf9?
We use optimized lipid-based transfection (lipofection) or electroporation protocols to deliver the CRISPR plasmids or the highly efficient RNP complex (Cas9 protein + gRNA) into the target insect cell line.
5. What is the benefit of deleting native protease genes?
Deleting native proteases prevents the degradation of the valuable recombinant protein after it is secreted or during cell lysis, ensuring a higher final yield of intact, full-length product.
6. How does Base Editing help optimize the insect cell host?
Base Editing allows for subtle, precise changes (single-nucleotide substitution) to tune promoter strength or optimize the activity of endogenous folding enzymes (e.g., PDI) without the need for large insertion/deletion events.
7. Are the final engineered cell lines stable?
Yes. By utilizing CRISPR-mediated stable genomic integration (knock-in), the transgenes become a permanent part of the insect cell chromosome, ensuring consistent expression and stability over many passages, unlike transient viral expression.
8. What types of insect cell lines do you support?
We support all major insect cell lines used in bioproduction, including Spodoptera frugiperda (Sf9, Sf21) and Trichoplusia ni (High Five, Hi5), optimizing protocols based on the specific cell line's characteristics.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.